Week 06, 2018pdf, World Health Organization, SouthEast Asia Regional Office

(1)

Data Sources: Ministries of Health in SEAR Countries.

Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi

–

110002, India

Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:

http://www.searo.who.int/topics/immunization/

Vol. 22, Week 06, 2018

Published 12 February 2018

Meetings/ Important events:



Regional Consultation on Human Papilloma Vaccine Introduction, New Delhi, India, 28-30 March 2018

**Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 12 February 2018)**

**Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 12 February 2018)**

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

C

li

n

ic

a

ll

y-co

n

fi

rm

e

d

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

Bangladesh 252 90 97 244 100 97 93 105 0 7 12 121 7 48 0.04 75 6.22 7.39

Bhutan 0 0 0 0 0 0 0 0 0 0 0 0.00 65 0.00 0.00

DPR Korea 0 0 0 0 0 0 0 0 0 0 0 0.00 0.00 0.00

India3 _{1 192} ₀ ₄₁ ₄₆₁ ₆₂ ₇₃ ₆₆ ₂₇₂ ₀ ₀ ₈ ₄₉ ₈₆₃ ₄ _0.59 ₅ _1.86 _0.39

Indonesia4

2 0 100 0 0 0 0 0 0 0 2 0 0.01 0.00 0.00

Maldives 2 50 100 2 0 1 50 0 0 0 0 0 2 0 5.07 60 0.00 0.00

Myanmar 8 100 88 7 100 0 0 0 0 0 0 0 8 0 0.13 14 0.00 0.00

Nepal 32 0 100 3 100 0 0 0 0 0 0 0 32 0 1.02 55 0.00 0.00

Sri Lanka 0 0 0 0 0 0 0 0 0 0 0 0 0.00 23 62.00 0.42

Thailand 304 32 86 232 80 58 95 1 85 1 120 2 39 0.03 24.13 16.13

Timor-Leste 37 97 95 35 100 74 74 0 0 0 0 25 12 68 8.58 38 0.00 178.75

SEAR 1 829 20 59 984 77 85 70 472 1 92 21 315 928 159 0.05 2.61 1.55

1_{Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases} 4_{A lso includes the cases fro m enhanced measles case-based surveillance.}

ND=No data

2

Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per 100,000 popn

Mea s l es

i nci dence1 per mi l l i on

popn % s erum

s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a

i nci dence2 per mi l l i on

popn

Mea s l es Rubel l a

D

is

ca

rd

e

d

n

o

n

-m

e

a

sl

e

s

n

o

n

-ru

b

e

ll

a

c

a

se

s

P

e

n

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

s erum s peci mens recei ved i n l a bora tory

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

C

li

n

ic

a

ll

y-co

n

fi

rm

e

d

La

b

o

ra

to

ry

-c

o

n

fi

rm

e

d

E

p

id

e

m

io

lo

g

ic

a

ll

y-co

n

fi

rm

e

d

Bangladesh 8 218 92 80 6 577 100 100 64 2 709 961 512 240 58 3 738 0 2.40 80 26.81 1.91

Bhutan 221 84 79 166 59 46 14 0 0 2 0 160 45 21.47 55 18.79 2.68

DPR Korea 105 100 100 105 100 100 99 0 0 0 0 0 105 0 0.42 0.00 0.00

India3 _{20 148} ₀ ₃₀ _{5 788} ₉₂ ₉₇ ₆₆ _{3 240} _{5 803} ₀ ₇₄₅ _{1 998} _{2 695} _{5 667} _0.21 ₃ _7.15 _2.17

Indonesia4

10 685 0 99 0 0 0 0 0 0 0 10 685 0.00 0.00 0.00

Maldives 66 97 100 66 100 100 71 1 0 0 1 0 59 5 17.26 15 2.93 2.93

Myanmar 1 731 40 88 1 526 99 100 94 1 019 205 74 4 0 424 5 0.82 11 25.24 0.08

Nepal5 _{1 031} ₂₁ ₉₁ ₅₁₄ ₆₆ ₇₃ ₆₅ ₂₄ ₁₁ ₂₁ ₀ ₈₂₆ ₈₄ _3.02 ₅₆ _3.66 _0.77

Sri Lanka 242 98 89 212 92 100 64 1 0 22 2 0 217 0 1.05 27 62.00 0.42

Thailand 2 989 28 86 2 449 58 95 58 1 453 16 546 24 0 857 93 1.32 31.06 0.37

Timor-Leste 145 100 99 137 100 74 57 0 0 0 9 0 130 6 10.73 46 0.00 7.43

SEAR 45 581 22 63 17 540 90 100 67 8 502 7 009 1 165 1 048 2 056 9 211 16 590 0.49 8.94 1.66

1

Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases 4

A lso includes the cases fro m enhanced measles case-based surveillance. ND=No data

2

Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases 5

So me Lab data variables no t available.

3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry

* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.

%

s peci mens tes ted for s erol ogy

of s peci mens

recei ved i n the l a bora tory

% s erol ogy res ul ts reported w/i n 4 da ys

of s peci men recei ved a t l a bora tory

Case classification (number)

Reporti ng ra te of di s ca rded

non-mea s l es non-rubel l a ca s es a t the na ti ona l l evel per 100,000 popn

% di s tri cts reporti ng a t

l ea s t 2 di s ca rded

non-mea s l es non-rubel l a

ca s es per

100,000 popn Mea s l es i nci dence1

per mi l l i on

popn % s erum

s peci mens recei ved a t l a bora tory w/i n 5 da ys of col l ecti on

Rubel l a i nci dence2

per mi l l i on

popn

Mea s l es Rubel l a

D

is

ca

rd

e

d

n

o

n

-m

e

a

sl

e

s

n

o

n

-ru

b

e

ll

a

c

a

se

s

P

e

n

d

in

g

c

la

ss

if

ic

a

ti

o

n

Countries

Number of s us pected mea s l es

ca s es % s us pected ca s es wi th a dequa te i nves ti ga ti

on i ni ti a ted

w/i n 48 hours of noti fi ca ti on

% s us pected ca s es wi th s erum s peci mens

col l ected Number of

(2)

Vol. 22,

Week 06, 2018

Vaccine Preventable Disease Surveillance Bulletin

Page 2

Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 12 February 2018)

Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 12 February 2018)

T

o

ta

l

>

9

0 D

a

y

s

3

T

o

ta

l

>

9

0 D

a

y

s

3

Bangladesh

1 368

0

0 1 351

17

16

2.75

2.71

98

99

74

0

32

42

0

1.29

0.56

100

100 Bhutan

9

0

7

2

1

3.64

2.83

89

100

0

0.00

0

0 DPR Korea

104

0

75

29

27

1.82

1.31

97

100

0

0.00

0

0 India

39 287

0

14 37 432 1 841 1 126

8.96

8.54

86

98 2 273

0

0 1 165 1 108

0

4.49

2.30

87

96 Indonesia

1 614

0

1 1 411

202

162

2.30

2.01

83

97

33

0

16

17

0

0.41

0.20

97

100 Maldives

6

0

5

1

0

6.34

5.29

67

100

0

0.00

0

0 Myanm ar

394

0

376

18

1

2.92

2.79

95

100

21

0

21

0

1.35

0.00

100

100 Nepal

364

0

360

4

3

4.20

4.15

98

100

19

0

12

7

0

1.90

1.20

100

100 Sri Lanka

70

0

69

1

1.29

1.27

84

100

5

0

3

2

0

0.80

0.48

80

100 Thailand

187

0

131

56

36

1.62

1.13

67

92

2

0

2

0

0.15

0.00

100

100 Tim or-Leste

3

0

1

2

1

0.65

0.22

33

100

0

0.00

0

0 SEAR

43 406

0

15 41 218 2 173 1 374

7.18

6.82

86

98 2 427

0

0 1 228 1 199

0

3.48

1.76

88

96

3

_{90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.}

2

_{AFP rates per 100,000 children aged <15 years using population figures provided by member countries (AFP cases > 15 years of age or missing age information are excluded).}

%

w

it

h

a

n

y

s

p

e

c

im

e

n

1

_{All countries are using the virologic classification scheme.}

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2 s

p

e

c

.,

a

t

le

a

s

t

2

4 h

rs

a

p

a

rt

,

w

/i

n

1

4 d

a

y

s

N

o

n

-P

o

li

o

A

F

P

R

a

te

%

w

it

h

2 s

p

e

c

.,

a

t

le

a

s

t

2

4 h

rs

a

p

a

rt

,

w

/i

n

1

4 d

a

y

s

%

w

it

h

a

n

y

s

p

e

c

im

e

n

A

F

P

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

4

Country

Case Classification

1

Annualized

AFP Rates

2

Specim en

A

F

P

C

a

s

e

s

W

il

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

V

a

c

in

e

D

e

ri

v

e

d

P

o

li

o

v

ir

u

s

C

a

s

e

s

4

C

o

m

p

a

ti

b

le

D

is

c

a

rd

e

d

(N

o

n

-p

o

li

o

A

F

P

)

Pending

A

F

P

R

a

te

Case Classification

1

_{AFP Rates}

2

_{Specim en}

2017 (Onset)

2018 (Onset)

AFP

Surveillance Indicators

AFP

Surveillance Indicators

W

il

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7

Days

>7

days

W

il

d

V

a

c

in

e

W

il

d

V

a

c

in

e

V

D

P

V

W

il

d

V

a

c

in

e

<7

Days

>7

days

Bangladesh

IPH, Dhaka

20

0

8

0

7

5

0

2

0

2

0

0 Bhutan

NIH, Bangkok

0

0 DPR Korea

NPL, Pyongyong

0

0 BJMC, Ahmedabad

232

0

78

0

67

78

9

0

3

0

1

0

2

0 NIV, Bengaluru

152

0

57

0

35

45

15

0

1

0

1

0

0 ERC, Mumbai

155

0

51

0

47

36

21

0

2

0

1

0

1

0 SGPGI, Lucknow

286

0

57

0

100

63

25

41

0

7

0

2

0

3

1

0

1

0 KIPM, Chennai

50

0

10

0

26

14

0

0 NCDC, Delhi

205

0

58

0

89

50

8

0

4

0

1

0

1

0

2

0 IoS, Kolkatta

174

0

55

0

39

58

18

3

0

1

4

0

2

0

0 CRI, Kasauli

22

0

11

0

6

5

0

0 1 276

0

377

0

409

349

96

44

0

1

21

0

4

0

4

6

1

0

6

0 Bio Farma, Bandung

2

0

2

0

0 NIHRD, Jakarta

2

0

2

0

0 PHL, Surabaya

1

0

1

0

1

0

1

0

5

0

3

2

0

1

0

1

0

0 Myanm ar

NHL, Yangon

6

0

1

0

4

1

0

0 Nepal

NIH, Bangkok

5

0

3

2

0

0 Sri Lanka

MRI, Colombo

0

0 Thailand

NIH, Bangkok

5

0

2

0

3

0

0 1 317

0

388

0

429

359

96

44

0

1

24

0

4

0

6

7

1

0

6

0 Indonesia Total

TOTAL

N

P

E

V

b

y

P

C

R

N

E

V

N

e

g

a

ti

v

e

India

India Total

Indonesia

N

e

g

a

ti

v

e

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT

D

Polio 1

Polio 2

Polio 3

V

a

c

in

e

m

ix

tu

re

Polio 1

Polio 2

Polio 3

V

a

c

in

e

m

ix

tu

re

N

P

E

V

b

y

P

C

R

N

E

V

Country of

Case

ITD Labs

2017

2018

Intratypic Differentiation results

Results

pending

Intratypic Differentiation results

Results

pending

A

F

P

c

a

s

e

s

re

fe

rr

e

d

fo

r

IT